The Arkansas attorney general on May 11 accused drugmakers and pharmacy benefit managers of colluding to drive up the price of insulin drugs, the latest in a series of lawsuits to take aim at skyrocketing costs for the life-sustaining medicine.
The European Commission wants to make health data easier to access by 2025 for patients, medics, regulators and researchers in a bid to improve diagnoses, cut unnecessary costs from duplication of medical tests and boost medicine research.
Pfizer boosts respiratory drug portfolio with ReViral purchase April 7, 2022 By Bhanvi Satija April 7 (Reuters) – Pfizer Inc (PFE.N) said on Thursday it would buy privately-held ReViral Ltd […]
It’s no longer science fiction. The use of drones promises to provide those with chronic medical conditions with faster and easier access to the therapies they need.
During his first State of the Union Address, President Biden noted that the pandemic has been a disruptive force on multiple levels, not only for the United States but the entire globe. Among his pledges is a plan to distribute Pfizer’s antiviral drug Paxlovid free of charge to people who test positive.
According to Jon Bigelow, Executive Director of the Coalition for Healthcare Communication, the beginning of the Biden administration has had a largely positive impact on the biopharma industry, notably marked by an effort to “stick to the science”; a fairly efficient roll-out of COVID-19 vaccines that allows reopening of schools and many aspects of normal daily life; and expansion of Affordable Care Act (ACA) coverage. But behind the scenes, pressure continues to build surrounding high prescription drug costs and changes in tax policy.
Two weeks after AstraZeneca announced the company was withdrawing the use of Imfinzi as a treatment for bladder cancer in the United States, Swiss pharma giant Roche followed suit with the checkpoint inhibitor Tecentriq (atezolizumab).
Merck announced on March 1 the voluntary withdrawal of the U.S. indication for Keytruda (pembrolizumab) for the treatment of patients with metastatic small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy and at least one other prior line of therapy.
AstraZeneca will voluntarily withdraw the use of the company’s Imfinzi to treat advanced bladder cancer in the United States after the cancer drug failed to meet post-approval requirements, the Anglo-Swedish drugmaker said.
President Donald Trump signed a new executive order aimed at lowering drug prices in the United States by linking them to those of other nations and expanding the scope of a July 2020 action.